Analysts Offer Predictions for Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - William Blair reduced their Q1 2025 earnings estimates for Krystal Biotech in a note issued to investors on Wednesday, April 2nd. William Blair analyst S. Corwin now anticipates that the company will post earnings of $1.31 per share for the quarter, down from their prior forecast of $1.47. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q2 2025 earnings at $1.47 EPS, Q4 2025 earnings at $2.03 EPS, FY2025 earnings at $6.65 EPS, Q1 2026 earnings at $1.60 EPS, Q2 2026 earnings at $1.94 EPS and FY2026 earnings at $9.03 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the company posted $0.30 EPS. The company's revenue was up 116.4% compared to the same quarter last year.

Other research analysts have also recently issued reports about the company. HC Wainwright reissued a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Finally, Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and a consensus target price of $220.00.

Remove Ads

Krystal Biotech Trading Up 2.7 %

KRYS stock traded up $4.35 during trading on Monday, hitting $165.00. The company had a trading volume of 426,700 shares, compared to its average volume of 295,707. The company has a fifty day moving average price of $173.96 and a two-hundred day moving average price of $172.25. Krystal Biotech has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The company has a market cap of $4.75 billion, a P/E ratio of 55.18 and a beta of 0.75.

Institutional Trading of Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in KRYS. Summit Global Investments boosted its position in shares of Krystal Biotech by 36.4% in the 1st quarter. Summit Global Investments now owns 4,711 shares of the company's stock worth $849,000 after purchasing an additional 1,258 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Krystal Biotech by 50,249.4% during the first quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock worth $21,878,000 after buying an additional 121,101 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Krystal Biotech by 5.9% during the 4th quarter. California State Teachers Retirement System now owns 20,388 shares of the company's stock worth $3,194,000 after buying an additional 1,127 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Krystal Biotech during the 4th quarter worth about $3,634,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $95,000. Institutional investors own 86.29% of the company's stock.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).